Efficacy and safety of Hexuemingmu tablets for diabetic retinopathy：A Meta-analysis

Abstract

Methods: The PubMed, Cochrane Library, Web of Science, EmBase, China Biomedical Literature Service System,CNKI,VIP and Wangfang database were searched until March 1,2024. The database and the treatment of diabetic retinopathy were screened according inclusion and exclusion criteria , and meta-analysis was performed using Revman 5.3. Results:Twenty-two Chinese articles were included in a total of 2298 patients, including 1150 patients treated alone or together and Hexuemingmu tabletsin the experimental group and 1148 patients in the control group using conventional treatment. Meta-analysis showed the clinical effective rate(OR= 3.94,95%CI[2.97,5.22], P <0.001), visual acuity（MD=0.08，95%CI[0.07, 0.10]，P＜0.001）, angioma volume (MD= -4.31, 95%CI[-5.08, -3.54], P<0.001), macular thickness (MD= -54.68, 95%CI[-67.55, -41.80], P<0.001), Area of retinal hemorrhage (MD= -0.40, 95%CI[-0.51, -0.30], P<0.001). There was no statistically significant difference in adverse events rate.(OR=0.65,95%CI[0.34,1.22], P=0.18). Conclusion: The treatment of diabetic retinopathy with Hexuemingmu tablets can better improve their symptoms and signs, and have better effectiveness and safety.